Key results from the interim analysis of the Phase 3 ENLIGHTED study of Padeliporfin VTP: As of November 5, 2024, the data cut-off for the poster presentation at ASCO, 43 patients had begun treatment, ...

Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second lin ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...

Less than half of patients diagnosed with TD residing in LTC settings received the standard of care treatment recommended by the American Psychiatric Association – a vesicular monoamine transporter 2 ...

A copy of the Early Warning Report filed by CEO will be available under the Company’s profile on SEDAR at www.sedarplus.ca or may be obtained from José Roldan, Interim CFO, at jroldan@rammpharma.com.

The Company has experienced dramatic user growth over the past two years as can be seen by the consistent revenue growth over the past eight quarters. Net loss and comprehensive loss have improved ...

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today ...

Mont-Saint-Guibert (Belgique), le 30 mai 2025, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (“ 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA ...